Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 5/20 | 0.36 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852119 | 0.76 | TOP2A (0.42) | TOP2AADRA1AHRH1ADRA1BKAT2B | |
| SCHEMBL15880124 | 0.72 | ROCK1 (0.48) | TOP2AADRA1AHRH1ADRA1BROCK1 | |
| SCHEMBL17324830 | 0.72 | ROCK1 (0.48) | TOP2AADRA1AHRH1ADRA1BKAT2B | |
| SCHEMBL17321546 | 0.70 | ROCK1 (0.47) | TOP2AADRA1AHRH1ADRA1BKAT2B | |
| SCHEMBL15880333 | 0.69 | ROCK1 (0.48) | TOP2AADRA1AHRH1ADRA1BKAT2B | |
| SCHEMBL4850204 | 0.68 | GSK3B (0.46) | TOP2AADRA1AHRH1ADRA1BKAT2B | |
| SCHEMBL10832034 | 0.65 | TOP2A (0.45) | TOP2AADRA1AHRH1ADRA1BKAT2B | |
| SCHEMBL3974796 | 0.64 | SMN1; SMN2 (0.64) | ADRA1AHRH1ADRA1BSMN1; SMN2 | |
| SCHEMBL10831636 | 0.63 | GLS (0.45) | TOP2AADRA1AHRH1ADRA1BROCK1 | |
| Hydrochloric Acid SCHEMBL4087801 | 0.63 | SMN1; SMN2 (0.62) | ADRA1AHRH1ADRA1BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329657-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7304060-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050004202-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ZHANG HAN-CHENG (US) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004202-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | MAP2K2, MAP3K20, MAP2K3 | TOP2A 1429/4885ADRA1A 4273/4885HRH1 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.